Brief: FDA Grants Face-To-Face Meeting To Discuss Cytodyn’S 510(K) Application For Prostagene Prognostic Test
24/06/2019 11:13
June 24 (Reuters) - Cytodyn Inc CYDY.PK :
* FDA GRANTS FACE-TO-FACE MEETING TO DISCUSS CYTODYN’S
510(K)
APPLICATION FOR PROSTAGENE PROGNOSTIC TEST
Source text for Eikon: ID:nGNX8CSHw1
Further company coverage: CYDY.PK
(((Reuters.Briefs@thomsonreuters.com);;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer